Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on October 23, 2025, and filed on October 24, 2025. The Company, a foreign private issuer, executed a share repurchase through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than general financial performance metrics such as revenue or profit.
- Shares Purchased: 366,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,640.00 GBp; highest price paid was 1,657.50 GBp.
- Average Price: Volume-weighted average price paid was 1,648.10 GBp.
- Trading Venues: Transactions occurred on the London Stock Exchange (XLON), CBOE Europe (CHIX), and BATE.
- Treasury Holdings: Following this purchase, the Company holds 253,192,344 ordinary shares in treasury.
- Shares in Issue: 4,062,224,575 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.23% of the total voting rights.
Material Changes and Programme Progress
Since the commencement of the current non-discretionary agreement on September 30, 2025, the Company has purchased a total of 5,727,500 ordinary shares. The October 23 transaction represents a continuation of this programme. The filing confirms that the purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific transaction report.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since September 30, 2025 (stated as 5,727,500).
- Confirm the current percentage of voting rights held in treasury (stated as 6.23%) for disclosure threshold calculations.
- Review the "Risk Factors" section in the 2024 Form 20-F and Q2 2025 results for context on forward-looking statements.
- Check the total number of ordinary shares in issue (4,062,224,575) to ensure accurate denominator usage for ownership reporting.